11. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Issue 14 (6th December 2021) Authors: Levy, Ilana; Lavi, Avital; Zimran, Eran; Grisariu, Sigal; Aumann, Shlomzion; Itchaki, Gilad; Berger, Tamar; Raanani, Pia; Harel, Reut; Aviv, Ariel; Lavi, Noa; Zuckerman, Tsila; Shvidel, Lev; Jarchowsky, Osnat; Ellis, Martin; Herzog Tzarfati, Katrin; Koren-Michowitz, Maya; Sherf, Yehonatan; Levi, ... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 14(2021) Page Start: 3384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species‐ and GSK3β‐dependent mechanism. (31st January 2021) Authors: Samara, Aladin; Shapira, Saar; Lubin, Ido; Shpilberg, Ofer; Avigad, Smadar; Granot, Galit; Raanani, Pia Journal: British journal of haematology Issue: Volume 192:Number 4(2021) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Dual BRAF/MEK Blockade Restores CNS Responses in BRAF Mutant Erdheim Chester Disease Patients Following BRAF Inhibitor Monotherapy. Issue 2 (3rd March 2020) Authors: Mazor, Roei D; Weissman, Ran; Luckman, Judith; Domachevsky, Liran; Diamond, Eli L; Abdel-Wahab, Omar; Shapira, Shirley; Hershkovitz-Rokah, Oshrat; Groshar, David; Shpilberg, Ofer Journal: Neuro-oncology advances Issue: Volume 2:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy. Issue 1 (3rd March 2020) Authors: Mazor, Roei D; Weissman, Ran; Luckman, Judith; Domachevsky, Liran; Diamond, Eli L; Abdel-Wahab, Omar; Shapira, Shirley; Hershkovitz-Rokah, Oshrat; Groshar, David; Shpilberg, Ofer Journal: Neuro-oncology advances Issue: Volume 2:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017) Authors: Dimopoulos, Meletios A.; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San‐Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter‐Croneck, Adam; Magen, Hila; Mateos, Maria‐Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, ... Journal: British journal of haematology Issue: Volume 178:Number 6(2017) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Issue 11 (19th September 2021) Authors: Pasvolsky, Oren; Shargian, Liat; Rozovski, Uri; Wolach, Ofir; Ram, Ron; Shapira, Michael Y.; Avni, Batia; Stepensky, Polina; Israeli, Moshe; Vidal-Fisher, Liat; Shpilberg, Ofer; Raanani, Pia; Yeshurun, Moshe Journal: Leukemia & lymphoma Issue: Volume 62:Issue 11(2021) Page Start: 2747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Expedient synthesis and anticancer evaluation of dual‐action 9‐anilinoacridine methyl triazene chimeras. (19th August 2020) Authors: Walunj, Dipak; Egarmina, Katarina; Tuchinsky, Helena; Shpilberg, Ofer; Hershkovitz‐Rokah, Oshrat; Grynszpan, Flavio; Gellerman, Gary Journal: Chemical biology & drug design Issue: Volume 97:Number 2(2021) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Expedient synthesis and anticancer evaluation of dual‐action 9‐anilinoacridine methyl triazene chimeras. (19th August 2020) Authors: Walunj, Dipak; Egarmina, Katarina; Tuchinsky, Helena; Shpilberg, Ofer; Hershkovitz‐Rokah, Oshrat; Grynszpan, Flavio; Gellerman, Gary Journal: Chemical biology & drug design Issue: Volume 97:Number 2(2021) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Issue 10216 (21st December 2019) Authors: Poeschel, Viola; Held, Gerhard; Ziepert, Marita; Witzens-Harig, Mathias; Holte, Harald; Thurner, Lorenz; Borchmann, Peter; Viardot, Andreas; Soekler, Martin; Keller, Ulrich; Schmidt, Christian; Truemper, Lorenz; Mahlberg, Rolf; Marks, Reinhard; Hoeffkes, Heinz-Gert; Metzner, Bernd; Dierlamm, Judi... Journal: Lancet Issue: Volume 394:Issue 10216(2019) Page Start: 2271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. High incidence of silent cerebral infarcts in adult patients with beta thalassemia major. Issue 144 (August 2016) Authors: Pazgal, Idit; Inbar, Edna; Cohen, Maya; Shpilberg, Ofer; Stark, Pinhas Journal: Thrombosis research Issue: Issue 144(2016) Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗